Phio Pharmaceuticals (PHIO) Competitors $2.47 -0.06 (-2.37%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends PHIO vs. ELAB, BCDA, INDP, KPRX, AYTU, SNTI, MBIO, VCNX, GNPX, and EYENShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Elevai Labs (ELAB), BioCardia (BCDA), Indaptus Therapeutics (INDP), Kiora Pharmaceuticals (KPRX), Aytu BioPharma (AYTU), Senti Biosciences (SNTI), Mustang Bio (MBIO), Vaccinex (VCNX), Genprex (GNPX), and Eyenovia (EYEN). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. Elevai Labs BioCardia Indaptus Therapeutics Kiora Pharmaceuticals Aytu BioPharma Senti Biosciences Mustang Bio Vaccinex Genprex Eyenovia Phio Pharmaceuticals (NASDAQ:PHIO) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Is PHIO or ELAB more profitable? Phio Pharmaceuticals has a net margin of 0.00% compared to Elevai Labs' net margin of -223.41%. Elevai Labs' return on equity of -124.93% beat Phio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phio PharmaceuticalsN/A -134.57% -108.39% Elevai Labs -223.41%-124.93%-85.10% Do insiders & institutionals have more ownership in PHIO or ELAB? 57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 22.2% of Elevai Labs shares are held by institutional investors. 0.6% of Phio Pharmaceuticals shares are held by insiders. Comparatively, 37.0% of Elevai Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer PHIO or ELAB? Phio Pharmaceuticals currently has a consensus price target of $36.00, suggesting a potential upside of 1,357.49%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Phio Pharmaceuticals is more favorable than Elevai Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Elevai Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor PHIO or ELAB? In the previous week, Elevai Labs had 4 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 4 mentions for Elevai Labs and 0 mentions for Phio Pharmaceuticals. Elevai Labs' average media sentiment score of 0.44 beat Phio Pharmaceuticals' score of 0.00 indicating that Elevai Labs is being referred to more favorably in the news media. Company Overall Sentiment Phio Pharmaceuticals Neutral Elevai Labs Neutral Which has stronger earnings & valuation, PHIO or ELAB? Elevai Labs has higher revenue and earnings than Phio Pharmaceuticals. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Elevai Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.23Elevai Labs$1.71M6.08-$4.30M-$0.31-0.06 Does the MarketBeat Community favor PHIO or ELAB? Phio Pharmaceuticals received 36 more outperform votes than Elevai Labs when rated by MarketBeat users. CompanyUnderperformOutperformPhio PharmaceuticalsOutperform Votes3663.16% Underperform Votes2136.84% Elevai LabsN/AN/A SummaryElevai Labs beats Phio Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad StockEarnings9 hidden AI stocks set to thrive in Trump’s new eraAI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)Get the Name of These AI Picks Now Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.62M$6.54B$5.20B$8.81BDividend YieldN/A8.13%5.54%4.07%P/E Ratio-0.2310.1793.0017.57Price / SalesN/A324.561,208.7090.08Price / CashN/A53.8341.6136.95Price / Book0.5310.597.246.54Net Income-$10.83M$153.02M$119.89M$226.07M7 Day Performance11.76%3.96%2.14%3.77%1 Month Performance-16.55%-6.72%-2.24%4.46%1 Year Performance-70.80%30.92%32.71%27.57% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals1.4603 of 5 stars$2.47-2.4%$36.00+1,357.5%-70.5%$2.62MN/A-0.238ELABElevai Labs0.4952 of 5 stars$0.02flatN/A-99.4%$10.41M$1.71M0.0018News CoverageGap DownBCDABioCardia3.0772 of 5 stars$2.26+5.6%$25.00+1,006.2%-76.8%$10.35M$480,000.000.0016INDPIndaptus Therapeutics2.305 of 5 stars$1.00-3.8%$8.50+750.0%-52.2%$10.20MN/A0.006High Trading VolumeKPRXKiora Pharmaceuticals2.9899 of 5 stars$3.37+1.8%$10.00+196.8%-29.2%$10.11MN/A0.0010AYTUAytu BioPharma0.8265 of 5 stars$1.63+7.9%N/A-35.1%$10.02M$81M0.00160SNTISenti Biosciences0.828 of 5 stars$2.17+2.4%N/A-37.9%$9.96M$2.56M-0.144News CoverageMBIOMustang Bio1.5025 of 5 stars$0.21flat$2.00+875.1%-86.9%$9.80MN/A-0.13100Gap DownVCNXVaccinex0.5962 of 5 stars$3.62+0.6%N/A-71.4%$9.41M$570,000.00-0.0740GNPXGenprex3.9958 of 5 stars$1.10-3.5%$10.00+809.1%-89.4%$9.36MN/A0.0020Positive NewsEYENEyenovia2.8151 of 5 stars$0.11flat$2.00+1,758.7%-92.0%$9.30MN/A0.0040Analyst RevisionNews CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies ELAB Competitors BCDA Competitors INDP Competitors KPRX Competitors AYTU Competitors SNTI Competitors MBIO Competitors VCNX Competitors GNPX Competitors EYEN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHIO) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredOne coin could soar when Trump’s elected …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHIO Stock Alerts